67046-22-4Relevant academic research and scientific papers
Discovery of novel triazolobenzazepinones as γ-secretase modulators with central Aβ42 lowering in rodents and rhesus monkeys
Fischer, Christian,Zultanski, Susan L.,Zhou, Hua,Methot, Joey L.,Shah, Sanjiv,Hayashi, Ikuo,Hughes, Bethany L.,Moxham, Christopher M.,Bays, Nathan W.,Smotrov, Nadya,Hill, Armetta D.,Pan, Bo-Sheng,Wu, Zhenhua,Moy, Lily Y.,Tanga, Flobert,Kenific, Candia,Cruz, Jonathan C.,Walker, Deborah,Bouthillette, Melanie,Nikov, George N.,Deshmukh, Sujal V.,Jeliazkova-Mecheva, Valentina V.,Diaz, Damaris,Michener, Maria S.,Cook, Jacquelynn J.,Munoz, Benito,Shearman, Mark S.
, p. 3488 - 3494 (2015/08/06)
Abstract Synthesis and SAR studies of novel triazolobenzazepinones as gamma secretase modulators (GSMs) are presented in this communication. Starting from our azepinone leads, optimization studies toward improving central lowering of Aβ42 led to the discovery of novel benzo-fused azepinones. Several benzazepinones were profiled in vivo and found to lower brain Aβ42 levels in Sprague Dawley rats and transgenic APP-YAC mice in a dose-dependent manner after a single oral dose. Compound 34 was further progressed into a pilot study in our cisterna-magna-ported rhesus monkey model, where we observed robust lowering of CSF Aβ42 levels.
THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME
-
Page/Page column 172, (2008/06/13)
In part, the present invention is directed towards compounds with FabI inhibiting properties. Such compounds may also inhibit other enzymes, including those similar to FabI either structurally or functionally, for example, Fab K. Kits and compositions that include the disclosed compounds are also provided. Methods of treating a subject with a bacterial illness is also disclosed.
CYCLOALKANOPYRIDINE DERIVATIVE
-
Page/Page column 86, (2010/11/24)
Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.
Heterocyclic-fused lactams promote release of growth hormone
-
, (2008/06/13)
There are disclosed certain novel compounds identified as heterocyclic-fused lactams which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible
